抗血小板药物在急性心肌梗死治疗中的应用

Application of Antiplatelet Drugs in the Treatment of Acute Myocardial Infarction

急性心肌梗死是心内科常见的急危重症,目前针对急性ST段抬高型心肌梗死的治疗策略是实施早期再灌注治疗。尽早、完全、持续开通闭塞冠状动脉,恢复心肌水平的再灌注,能有效降低患者死亡率,改善患者预后。实施经皮冠状动脉介入(PCI)治疗是一种有效的再灌注策略,但在术后仍存在血栓性心血管事件发生风险。抗血小板药物越来越广泛被用于PCI术后预防不良心血管事件中,且取得一定效果。基于此,本文对抗血小板药物在急性心肌梗死PCI术后中的应用进行综述。

Acute myocardial infarction is a common critical illness in cardiology.The current treatment strategy for acute ST-segment elevation myocardial infarction is to implement early reperfusion therapy.Early,complete,and continuous opening and occlusion of coronary arteries and reperfusion to restore myocardial levels can effectively reduce patient mortality and improve patient prognosis.Percutaneous coronary intervention(PCI)is an effective reperfusion strategy,but there is still a risk of thrombotic cardiovascular events after surgery.Antiplatelet drugs are more and more widely used to prevent adverse cardiovascular events after PCI,and have achieved certain results.Based on this,this article reviews the application of antiplatelet drugs in PCI after acute myocardial infarction.